5th November, 2015

The Dy. General Manager (Listing Dept.)
BSE Limited
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Sub.: Communique under Clause 36 of the Listing Agreement**

Pursuant to Clause 36 of the Listing Agreement, we would like to inform you that the Company's new plant at Dahej commences its Operations.

A Press release on the said subject is enclosed herewith for your information.

Request you to kindly take note of it.

Thanking you,

Yours Sincerely,
For TORRENT PHARMACEUTICALS LIMITED

MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: A/a

**Torrent Pharma's new Plant at Dahej Commences operations**

5th November, 2015

Torrent Pharma, one of the leading pharma companies of the Country has commenced commercial operations at its new plant in Dahej. This is the Company's 5th formulation Plant and the 2nd API Plant. The facility is being set up in a two phases. The total investment made in the first phase of the plant is over Rs. 650 crores.

The new plant, situated in Dahej SEZ is spread across 70 acres site with a built up area of around 97000 sq. mtr. Phase I will have installed capacity of about 7,500 million tablets / capsules and 25 MT API per annum. The plant will cater mainly to the more regulated international markets such as US, Brazil, Germany etc. and is already approved / under approval by regulatory authorities of these countries.

Jinesh Shah, Executive Director at Torrent Pharma said, "This plant will scale up Torrent's manufacturing capacity to meet the growing demand from the international markets."

Construction of Phase II will commence soon and once commissioned the total capacity will increase to about 14,000 million tablets / capsules and 80 MT API per year.

**About Torrent Pharma**

Torrent Pharma, with annual revenues of almost Rs. 4700 crores is the flagship Company of the Torrent Group. Torrent continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands (AIOCD Dataset). Torrent has a full equipped Research Center, employing almost 600 scientists, to support the Company's operations and product pipeline for both Domestic and Overseas markets. The Company's existing manufacturing plants located at Indrad, Baddi & Sikkim have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.